These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 1510386)

  • 1. Why are nigral catecholaminergic neurons more vulnerable than other cells in Parkinson's disease?
    Hirsch EC
    Ann Neurol; 1992; 32 Suppl():S88-93. PubMed ID: 1510386
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Does oxidative stress participate in nerve cell death in Parkinson's disease?
    Hirsch EC
    Eur Neurol; 1993; 33 Suppl 1():52-9. PubMed ID: 8375433
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oxidative stress as a cause of nigral cell death in Parkinson's disease and incidental Lewy body disease. The Royal Kings and Queens Parkinson's Disease Research Group.
    Jenner P; Dexter DT; Sian J; Schapira AH; Marsden CD
    Ann Neurol; 1992; 32 Suppl():S82-7. PubMed ID: 1510385
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oxidative mechanisms in nigral cell death in Parkinson's disease.
    Jenner P
    Mov Disord; 1998; 13 Suppl 1():24-34. PubMed ID: 9613715
    [TBL] [Abstract][Full Text] [Related]  

  • 5. What process causes nigral cell death in Parkinson's disease?
    Jenner P
    Neurol Clin; 1992 May; 10(2):387-403. PubMed ID: 1584181
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuronal vulnerability in Parkinson's disease.
    Hirsch EC; Faucheux B; Damier P; Mouatt-Prigent A; Agid Y
    J Neural Transm Suppl; 1997; 50():79-88. PubMed ID: 9120427
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Altered mitochondrial function, iron metabolism and glutathione levels in Parkinson's disease.
    Jenner P
    Acta Neurol Scand Suppl; 1993; 146():6-13. PubMed ID: 8333254
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The enigma of neuromelanin in Parkinson's disease substantia nigra.
    Youdim MB; Ben-Shachar D; Riederer P
    J Neural Transm Suppl; 1994; 43():113-22. PubMed ID: 7884393
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New face of neuromelanin.
    Double KL; Halliday GM
    J Neural Transm Suppl; 2006; (70):119-23. PubMed ID: 17017518
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Current views on the mechanisms of dopaminergic neuron death of the nigrostriatal system in Parkinson's disease].
    Bertrand E; Lechowicz W; Szpak GM; Dymecki J
    Neurol Neurochir Pol; 1997; 31(2):295-302. PubMed ID: 9380259
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease.
    Halliday GM; Ophof A; Broe M; Jensen PH; Kettle E; Fedorow H; Cartwright MI; Griffiths FM; Shepherd CE; Double KL
    Brain; 2005 Nov; 128(Pt 11):2654-64. PubMed ID: 16000336
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is the vulnerability of neurons in the substantia nigra of patients with Parkinson's disease related to their neuromelanin content?
    Kastner A; Hirsch EC; Lejeune O; Javoy-Agid F; Rascol O; Agid Y
    J Neurochem; 1992 Sep; 59(3):1080-9. PubMed ID: 1494900
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The roles of neuromelanin, binding of metal ions, and oxidative cytotoxicity in the pathogenesis of Parkinson's disease: a hypothesis.
    Enochs WS; Sarna T; Zecca L; Riley PA; Swartz HM
    J Neural Transm Park Dis Dement Sect; 1994; 7(2):83-100. PubMed ID: 7710667
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does neuromelanin contribute to the vulnerability of catecholaminergic neurons in monkeys intoxicated with MPTP?
    Herrero MT; Hirsch EC; Kastner A; Ruberg M; Luquin MR; Laguna J; Javoy-Agid F; Obeso JA; Agid Y
    Neuroscience; 1993 Sep; 56(2):499-511. PubMed ID: 8247275
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased M-calpain expression in the mesencephalon of patients with Parkinson's disease but not in other neurodegenerative disorders involving the mesencephalon: a role in nerve cell death?
    Mouatt-Prigent A; Karlsson JO; Agid Y; Hirsch EC
    Neuroscience; 1996 Aug; 73(4):979-87. PubMed ID: 8809817
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Iron metabolism and Parkinson's disease.
    Hirsch EC; Faucheux BA
    Mov Disord; 1998; 13 Suppl 1():39-45. PubMed ID: 9613717
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuromelanin associated redox-active iron is increased in the substantia nigra of patients with Parkinson's disease.
    Faucheux BA; Martin ME; Beaumont C; Hauw JJ; Agid Y; Hirsch EC
    J Neurochem; 2003 Sep; 86(5):1142-8. PubMed ID: 12911622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clues to the mechanism underlying dopamine cell death in Parkinson's disease.
    Jenner P
    J Neurol Neurosurg Psychiatry; 1989 Jun; Suppl(Suppl):22-8. PubMed ID: 2666576
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective vulnerability of pigmented dopaminergic neurons in Parkinson's disease.
    Hirsch EC; Graybiel AM; Agid Y
    Acta Neurol Scand Suppl; 1989; 126():19-22. PubMed ID: 2575832
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The possible role of iron in the etiopathology of Parkinson's disease.
    Youdim MB; Ben-Shachar D; Riederer P
    Mov Disord; 1993; 8(1):1-12. PubMed ID: 8419792
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.